BioXcel Files for Chapter 11 as Teva Offers $57.5 Million Stalking-Horse Bid for Igalmi
BioXcel seeks Chapter 11 with a $19M DIP loan as Teva offers $57.5M plus milestones for Igalmi. Auction still open; sale not closed.
/ 491 items
#XY Event-Driven Stocks↓
Lisraya Wins FDA Approval as First Major Treatment Advance in Decades for Dermatomyositis
Newly approved Lisraya could become a blockbuster. J.P. Morgan calls dermatomyositis highly attractive and sees $2B+ U.S. peak sales.
Moderna Plans a $2 Billion Convertible-Note Sale After Last Week’s Cancer-Vaccine Rally
Moderna intends to sell $2B of zero-coupon notes due 2032, plus a $300M option, after a melanoma vaccine rally. Shares slipped on dilution risk.
Propanc Reports Over 90% Tumor Growth Inhibition and Survival Benefit for PRP in Pancreatic Cancer Models
Lead candidate PRP demonstrated strong tumor control, reduced metastatic spread, and a 2.5-fold increase in survival in preclinical pancreatic cancer studies.
FDA Grants Fast Track to CytomX’s Varseta-M in Relapsed Metastatic Colorectal Cancer
FDA grants Fast Track to CytomX’s Varseta-M for relapsed metastatic colorectal cancer as a 2027 pivotal trial and new combinations approach.
FDA Approves First Targeted RAS Drug for Metastatic Pancreatic Cancer
The FDA approved Revolution’s Rasonque, the first RAS-targeted daily pill for metastatic pancreatic cancer. It doubled median survival to 13.2 months, compared with 6.7 months with chemotherapy.